Theriva Biologics, Inc. — 10-Q Summary
Filing identity: The supplied filing is for Synthetic Biologics, Inc., not Theriva Biologics, Inc. It covers the quarter and nine months ended September 30, 2013, and was signed November 14, 2013. Financial statements are unaudited.
Business context and reporting period
Synthetic Biologics was a clinical-stage biotechnology company developing therapies for infectious diseases and multiple sclerosis, with fibromyalgia development partnered to Meda AB. Its pipeline included oral enzyme candidate SYN-004, monoclonal antibody candidates SYN-005 and SYN-001, and Trimesta. The company had sold its Adeona Clinical Laboratory business in 2012.
Financial performance and liquidity
| Metric | Q3 2013 | Q3 2012 | Nine months 2013 | Nine months 2012 |
|---|---|---|---|---|
| Revenue | No revenue reported | No revenue reported | No revenue reported | No revenue reported |
| Operating expenses | $3.365m | $1.836m | $8.066m | $5.413m |
| Loss from continuing operations | $3.368m | $1.826m | $8.093m | $5.391m |
| Net loss | $3.368m | $1.930m | $8.093m | $5.002m |
| Operating cash used | Not provided | Not provided | $5.015m | $4.143m |
Margins are not meaningful because the statements report no revenue. Q3 general and administrative expense was $1.890m and R&D was $1.475m; for the nine months, those expenses were $4.270m and $3.796m, respectively. The balance sheet reported cash of $5.145m, current assets of $6.792m, current liabilities of $0.584m, and stockholders’ equity of $6.369m at September 30. Working capital was approximately $6.208m. No debt is reported.
Cash declined $4.809m from year-end 2012. Nine-month investing cash use was $0.025m, and financing provided $0.231m, from stock-option exercises. The company reported a $77.034m accumulated deficit. It disclosed no committed financing, while noting an available ATM facility of up to $15m that had not been used as of the filing.
Material changes versus the prior comparable period
- Q3 operating expenses rose about 83% year over year; nine-month expenses rose about 49%. Management attributed R&D growth mainly to added personnel and infectious-disease program costs.
- Nine-month net loss increased to $8.093m from $5.002m, while operating cash use increased to $5.015m from $4.143m.
- In Q3 2013, the company deemed the $0.700m note receivable from the laboratory sale and related interest uncollectible, recording $0.763m of bad-debt expense. The note receivable was zero at September 30.
- Cash fell from $9.954m at December 31, 2012 to $5.145m at September 30, 2013. Stockholders’ equity was only $0.369m above the NYSE MKT minimum cited in the risk factors.
Outlook, management commentary, risks and unusual items
- Management expected continued substantial spending on research, preclinical work, clinical trials, and manufacturing, and warned that additional capital may be needed sooner or in greater amounts than anticipated. Failure to obtain financing could force delays, curtailment, or discontinuation of programs; equity financing could dilute shareholders.
- As of the filing, SYN-004 manufacturing had begun; a Phase I trial was anticipated in the second half of 2014. For SYN-005, an IND-enabling large-animal study was planned for Q1 2014, with results expected in Q2 2014 and a Phase I trial planned for Q2 2015. Trimesta’s relapsing-remitting MS Phase II trial was fully enrolled, with top-line results expected in the first half of 2014; its cognitive-dysfunction study was still enrolling.
- The filing cited clinical, regulatory, manufacturing, intellectual-property, collaborator, and competitive risks. It also noted that grant support was expected to fund the ongoing relapsing-remitting MS trial through completion, subject to cost assumptions.
- Management said disclosure controls were effective and reported no material change in internal control over financial reporting. No legal proceedings were reported.
Important facts for investors to verify
- Confirm the issuer: this filing names Synthetic Biologics, Inc.; the request metadata names Theriva Biologics, Inc.
- Reconcile per-share loss disclosures: the statements report Q3 net loss per share of $0.08, while MD&A describes continuing-operations loss per share as $0.06. For nine months, the statements report continuing-operations loss per share of $0.18, while MD&A says $0.16.
- Reconcile the bad-debt charge: the note reports $0.763m for the uncollectible note and interest; MD&A cites $0.763m for Q3 but $0.736m in its nine-month discussion.
- Assess cash needs and financing availability against the $5.145m cash balance, continued operating cash outflows, the unused ATM facility, and the narrow reported cushion over the cited NYSE MKT equity minimum.
- Track the planned clinical milestones and funding assumptions; the filing’s timelines were forward-looking and subject to clinical, regulatory, operational, and financing risks.